Advertisement

Topics

Inozyme Gets $49M From Sanofi, Novo to Tackle Rare Infant Disease

06:55 EST 15 Nov 2017 | Xconomy

Sanofi and Novo Nordisk this morning have put their venture arms to work. The two joined up with two venture firms to back a $49 million round for a fledgling startup, Inozyme Pharmaceuticals. The company aims to develop a therapy for an ultra-rare infant disorder—and possibly some more prevalent diseases too. The startup, based in […]

Original Article: Inozyme Gets $49M From Sanofi, Novo to Tackle Rare Infant Disease

NEXT ARTICLE

More From BioPortfolio on "Inozyme Gets $49M From Sanofi, Novo to Tackle Rare Infant Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Sanofi-Aventis
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...